# Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer

> **NCT01275859** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 25 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Letrozole, Lapatinib

## Key facts

- **NCT ID:** NCT01275859
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2014-04
- **Final completion:** 2014-05
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01275859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01275859, "Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01275859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*